MTL-CEBPA is under clinical development by Mina Therapeutics and currently in Phase II for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). According to GlobalData, Phase II drugs for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MTL-CEBPA LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTL-CEBPA is under development for the treatment of acute myeloid leukemia (AML),non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), liver failure and solid tumors including hepatocellular carcinoma, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, gall bladder cancer, neuroendocrine tumor, fallopian tube cancer, renal cancer, malignant mesothelioma, melanoma, glioblastoma multiforme, cholangiocarcinoma and mucopolysaccharidosis I (MPS I) hurler syndrome. The therapeutic candidate is administered through intravenous route. It is a SMARTICLES liposomal formulation of MTL-501. MTL-501 is a short activating RNA targeting the CEBPA gene. It is developed based on SMARTICLES delivery technology. SMARTICLES are amphoteric liposomes composed of combinations of lipids having anionic and cationic groups that work together to enable cell uptake. It was under development for the treatment of liver cirrhosis.
Mina Therapeutics overview
Mina Therapeutics, a subsidiary of MiNA (Holdings) Ltd, is a developer of small activating ribonucleic acid therapeutics that selectively upregulate therapeutic proteins. The company’s lead therapeutic, MTL-CEBPA, is developed for the treatment of liver cancer. It also offers evaluation programs for the treatment of liver cirrhosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and other medical conditions. Mina Therapeutics develops therapeutics using its proprietary RNA activation technology platform. The company collaborates with drug delivery companies for the development of saRNA. It operates through its offices and laboratories in the UK. Mina Therapeutics is headquartered in London, Greater London, the UK.
For a complete picture of MTL-CEBPA’s drug-specific PTSR and LoA scores, buy the report here.